Moleculin Biotech (MBRX) Enterprise Value (2016 - 2025)
Moleculin Biotech's Enterprise Value history spans 10 years, with the latest figure at -$8.9 million for Q4 2025.
- Quarterly results put Enterprise Value at -$8.9 million for Q4 2025, down 107.53% from a year ago — trailing twelve months through Dec 2025 was -$8.9 million (down 107.53% YoY), and the annual figure for FY2025 was -$8.9 million, down 107.53%.
- Enterprise Value for Q4 2025 was -$8.9 million at Moleculin Biotech, down from -$6.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4.3 million in Q4 2024 to a low of -$86.3 million in Q1 2021.
- The 5-year median for Enterprise Value is -$28.4 million (2023), against an average of -$36.0 million.
- The sharpest move saw Enterprise Value plummeted 640.84% in 2021, then soared 81.83% in 2024.
- Year by year, Enterprise Value stood at -$70.9 million in 2021, then skyrocketed by 39.15% to -$43.1 million in 2022, then skyrocketed by 45.42% to -$23.6 million in 2023, then soared by 81.83% to -$4.3 million in 2024, then crashed by 107.53% to -$8.9 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$8.9 million, -$6.7 million, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.